Ken Hamill
Posted by

Taking on Precision Medicine with Industrialized Proteomics

[post-views]
views
Share on linkedin
Share on twitter
Share on email

White House, EU, UK, and Australia Make Major Investments

What if we could deliver the right treatment at the right time, to the right person to better, more effectively treat complex disease? This is the promise of precision medicine, to be able to approach complex disease treatment and prevention by taking into account individual variability in genes, environment, and lifestyle for each person.

Many of today’s medical treatments have been designed for the masses while the promise of precision medicine is to build treatments that are constructed around specific disease and individual characteristics. For example, if the genetic profile of an individual’s tumour could be measured, physicians can better manage cancer treatment by using the right drug for that genetic profile, which should lead to better outcomes and reduced adverse effects.

New White House Initiative Announced – USA
During President Obama’s 2015 State of the Union address, he announced the launch of the Precision Medicine Initiative (PMI). This new research effort is slated to revolutionize how we improve health and treat disease. In December 2015, President Obama signed into law a budget agreement that earmarked $200 million specifically for the advancement of precision medicine.

Watch Jo Handelsman, Associate Director for Science in the Office of Science and Technology Policy, explains the Precision Medicine Initiative and its significance.

EU Personalized and Precision Medicine Initiatives
Numerous efforts in the EU are promoting advances in precision medicine. As an example, a European Parliament brief on personalized medicine highlights how the Luxembourg Council Presidency has made personalized medicine one of its health priorities. The Innovative Medicines Initiative (IMI), another public/private partnership, facilitates collaborations between key stakeholders and provides financial support to major research projects, with the goal of accelerating development of new treatments. The initiative’s second phase, IMI 2, started in 2014. Its goal is to develop next-generation vaccines, medicines, and treatment, in particular, new and approved diagnostic markers for immunological, respiratory, neurological and neurodegenerative diseases. The total budget for IMI 2 is €3 276 billion.

UK Establishes The Precision Medicine Catapult
Established in April 2015, the Precision Medicine Catapult is the UK’s new national innovation centre for precision medicine. Its aim is to make the UK the most attractive place in the world in which to develop precision medicine test and therapies. It is funded by Innovate UK, the Government’s innovation agency, and has been funded with £50m in its first five years.  It will partner with precision medicine clusters across the UK to deliver a national strategy while also bringing impact to local healthcare.

Australia’s Children’s Medical Research Institute (CMRI) Works to Advance Precision Medicine
The high throughput ProCan facility will be established with $10 million in seed money from The Australian Cancer Research Foundation. Over the next five years, scientists at CMRI will analyze tens of thousands of examples of all types of cancer from all over the world to develop a library of information to advance scientific discovery and enhance clinical treatment worldwide. These studies will profile thousands of tumour samples per year, enable discoveries around the causes of cancer, provide guidance of cancer treatment options, and work to produce standard operating procedures for other facilities around the world.

The SCIEX Solution
As the promise of precision medicine continues to evolve, researchers will need powerful tools and application support to perform the Omics research that creates the scientific foundation of precision medicine. SCIEX industrialized proteomics solutions, using SWATH® Acquisition-based workflows and powered by the cloud with the OneOmics™ Project, will enable large-scale proteome studies to advance research. 

SCIEX Partners with University of Manchester to Develop Biomarker Discovery Centre and Multi-Omics Centre for Precision Medicine >

Learn How SCIEX and Children’s Medical Research Institute Have Joined Forces to Advance the Promise of Precision Medicine > 

With SCIEX technologies, you can accelerate the pace of your research to identify key genes, proteins, lipids and metabolites in complex systems biology and then integrate your findings to gain a comprehensive insight to further understand health and disease.

Want to know more about available methods? Comment below!

Ken Hamill
Posted by

Leave a Reply